The US Food and Drug Administration has approved Brytly, Alcon’s apraclonidine 0.125 percent eye drops, for nonprescription relief of eye redness due to minor irritation, the company announced on October 16. It is the first over the counter product containing apraclonidine, an alpha 2 adrenergic agonist whose higher concentration prescription forms are used to lower eye pressure. The approval covers adults and children aged 12 and older.
Alcon’s pitch is duration. The company says one drop begins reducing redness within one minute and lasts up to 12 hours, which it presents as up to 50 percent longer than Bausch and Lomb’s Lumify. That comparison is arithmetic on the two labels, 12 hours against eight, not the result of a head to head trial, and Alcon cites company data on file for a low risk of rebound redness with use as directed.
The FDA’s conditions are the standard ones for the class. Brytly should not be used more than twice a day, contact lenses must be removed before use and left out for at least 10 minutes, and users should stop and see a doctor for eye pain, vision changes, or redness that persists or worsens beyond three days. Expanding access to safe and effective nonprescription treatments is a priority for FDA, the agency’s drug centre director Mike Davis said in the approval statement.
Commercially this is a shelf space fight, not a therapeutic breakthrough. Alcon, the largest eye care company, already sells dry eye and contact lens products through the same retailers where Brytly will appear in the coming months, and a longer labelled duration is a legible consumer claim. Whether it moves Lumify’s established brand is a marketing question the approval itself does not answer.